A Case Report of a Patient Carrying CYP2C9*3/4 Genotype with Extremely Low Warfarin Dose Requirement
Journal of Korean Medical Science
;
: 557-559, 2007.
Artículo
en Inglés
| WPRIM
| ID: wpr-89788
ABSTRACT
We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Farmacogenética
/
Polimorfismo Genético
/
Tiempo de Protrombina
/
Fibrilación Atrial
/
Warfarina
/
Hidrocarburo de Aril Hidroxilasas
/
Relación Normalizada Internacional
/
Genotipo
/
Heterocigoto
/
Anticoagulantes
Límite:
Anciano
/
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Journal of Korean Medical Science
Año:
2007
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS